Unoprostone Isopropyl

Summary

Unoprostone Isopropyl (CHEMBL1200661) is an approved small-molecule antiglaucoma drug; indicated across 2 conditions including retinitis pigmentosa and age-related macular degeneration.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 424.6 Da · C25H44O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200661
Name	Unoprostone Isopropyl
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5282175
ChEBI	CHEBI:31731
Molecular formula	C25H44O5
Molecular weight	424.6
InChIKey	XXUPXHKCPIKWLR-JHUOEJJVSA-N

SMILES: CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O)O

IUPAC name: propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoate

ChEBI definition: The isopropyl ester of unoprostone.

Pharmacological roles (ChEBI): antiglaucoma drug, antihypertensive agent, prodrug.

Also known as: Isopropyl unoprostone, Rescula, UF-021, Unoprostone isopropyl, Unoprostone isopropyl ester, UNOPROSTONE ISOPROPYL, unoprostone isopropyl ester, SID144207178, unoprostone isopropyl

Patent coverage: 570 distinct patent families (2,396 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2C adrenergic receptor, Sodium channel protein type 5 subunit alpha, Progesterone receptor, Sodium-dependent noradrenaline transporter, Sodium-dependent dopamine transporter, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, Melanocortin receptor 3.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2B	6.05	AC50	890	nM	CHEMBL_ACT_25227769
ADORA3	5.25	AC50	5600	nM	CHEMBL_ACT_25134462
SLC6A3	5.14	AC50	7200	nM	CHEMBL_ACT_25124203
SLC6A2	5.14	AC50	7200	nM	CHEMBL_ACT_25145252
PDE4D	5.02	AC50	9600	nM	CHEMBL_ACT_25185587

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
retinitis pigmentosa	3	MONDO:0019200	MONDO:0019200
age-related macular degeneration	2	MONDO:0005150	EFO:0001365

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT01379560	PHASE2	COMPLETED	A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).